Baffert, Fabienne,Radimerski, Thomas,Gadbaw, Brian
申请号：
AU2017204469
公开号：
AU2017204469A1
申请日:
2017.06.29
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
#$%^&*AU2017204469A120170720.pdf#####H: dar Interoe NRPortbl DCC DAR 1I5006698_1doc-29/06/2017 ABSTRACT The invention relates to a combination which comprises: (a) Compound A ((R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile) of Formula (A): N N-N N H (A) or a pharmaceutically acceptable salt thereof； and (b) Compound B (N-hydroxy-3-[4-[[[2(2-methyl-iH-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide) of Formula (B): N OH H H NN H (B), or a pharmaceutically acceptable salt thereof； for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating proliferative diseases, in a mammal, particularly a human, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination.WO 20121174061 PCTIJS2012I(J42174 EE CD 00 D CL 0 >；00 M 0 C/,) cui 0 (D CE COo T- aw 0 U)w 141M 91d E -z O uD U) 0. (0 U-U (~rns ； 8/23
